GlassScriptPhysician profile
John Q Adams
NPI 1770524340
$4,635.21
in general payments reported to CMS, 2019-2025
33 companies · $396 in 2025
The $396 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $339 · 2021: $1,189 · 2022: $1,088 · 2023: $619 · 2024: $577 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,121.92 | 2019-2023 | Liletta |
| Mayne Pharma Commercial LLC | $872.03 | 2021-2025 | |
| Daiichi Sankyo INC. | $415.15 | 2019-2025 | Injectafer |
| Myriad Women'S Health, INC. | $315.76 | 2023 | Myrisk |
| Astellas Pharma US INC | $277.90 | 2022-2025 | Veozah |
| Organon LLC | $268.10 | 2021-2024 | Nexplanon |
| Pacira Pharmaceuticals Incorporated | $161.59 | 2021-2024 | Exparel |
| Pfizer INC. | $124.84 | 2019-2023 | |
| Therapeuticsmd, INC. | $112.22 | 2019-2022 | |
| Lupin INC. | $98.96 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $95.86 | 2019-2022 | |
| Biogen, INC. | $87.85 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $78.83 | 2023-2024 | Accrufer |
| Agile Therapeutics, INC. | $72.30 | 2021-2024 | Twirla |
| Scynexis, INC. | $71.31 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $57.39 | 2020-2022 | |
| Hologic Sales and Service, LLC | $51.11 | 2024 | Aptima |
| Myovant Sciences INC. | $50.42 | 2021-2022 | |
| Millicent US INC | $35.55 | 2025 | Intrarosa, Femring, Femlyv |
| Amag Pharmaceuticals, INC. | $33.56 | 2019 | |
| Sumitomo Pharma America, INC. | $33.28 | 2023-2024 | Myfembree |
| Avion Pharmaceuticals | $31.02 | 2021 | |
| Aspira Women'S Health INC | $24.81 | 2024 | Ova1 |
| Exeltis, USA INC. | $20.34 | 2020 | |
| Ethicon US, LLC | $19.50 | 2019 | |
| Almatica Pharma LLC | $19.50 | 2022 | |
| Mission Pharmacal Company | $16.07 | 2021 | |
| Covidien LP | $15.55 | 2019 | |
| Novo Nordisk INC | $14.32 | 2022 | |
| Meditrina | $13.49 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.69 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.